FDA Imposes Partial Hold On DBV Technologies' Phase III VITESSE Study
Source: NASDAQ US Markets / 22 Sep 2022 10:38:31 America/New_York
(RTTNews) - DBV Technologies' (DBVT) phase III study of modified Viaskin Peanut 250 µg patch, dubbed VITESSE, has been slapped with a partial clinical hold by the FDA.
https://www.nasdaq.com/articles/fda-imposes-partial-hold-on-dbv-technologies-phase-iii-vitesse-study